Inamrinone Lactate

CHEMBL2096642 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

277.3 g/mol

LogP

—

Phase

4

A lactate form of inamrinone with the same therapeutic properties. A phosphodiesterase inhibitor used short-term for severe heart failure.

Moleküler Ağırlık

277,2800 g/mol

TPSA

126,00 Å²

Terapötik Alanlar

Hypertension

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(O)C(=O)O.Nc1cc(-c2ccncc2)c[nH]c1=O

InChI

InChI=1S/C10H9N3O.C3H6O3/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7;1-2(4)3(5)6/h1-6H,11H2,(H,13,14);2,4H,1H3,(H,5,6)

Molecular Formula

C13H15N3O4

HBD / HBA

4 / 6

Döndürülebilir Bağlar

2

Ağır Atomlar

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A lactate form of inamrinone with the same therapeutic properties. A phosphodiesterase inhibitor used short-term for severe heart failure.

Yes, Inamrinone Lactate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2096642. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3035194. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Inamrinone Lactate PillFYI'da

Yapı

Hızlı Veriler

Formül: C13H15N3O4

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.